Strata Oncology Launched StrataNGS

Strata Oncology has launched StrataNGS, a 90-gene targeted next-generation sequencing assay that focuses on actionable genetic alterations in tumor tissue. The test has a 10-day turnaround time and analyzes both DNA and RNA from either fresh or archival biopsy tissue.